Focal Spot, Spring 1978

https://digitalcommons.wustl.edu/focal_spot_archives/1020/thumbnail.jp

Workers with Disabilities: The Role of Workplace Flexibility

A fact sheet for Workers with Disabilities: The Role of Workplace Flexibility covering the following: 1) What are the trends in workforce participation of individuals with disabilities? 2) How does the structure of work limit the employment of people with disabilities? 3) What is the role of workplace flexibility in the employment of individuals with disabilities? 4) The need for flexibility among people with disabilities matches the growing interest in flexibility for all workers

Prognostic value of routine laboratory variables in prediction of breast cancer recurrence.

The prognostic value of routine laboratory variables in breast cancer has been largely overlooked. Based on laboratory tests commonly performed in clinical practice, we aimed to develop a new model to predict disease free survival (DFS) after surgical removal of primary breast cancer. In a cohort of 1,596 breast cancer patients, we analyzed the associations of 33 laboratory variables with patient DFS. Based on 3 significant laboratory variables (hemoglobin, alkaline phosphatase, and international normalized ratio), together with important demographic and clinical variables, we developed a prognostic model, achieving the area under the curve of 0.79. We categorized patients into 3 risk groups according to the prognostic index developed from the final model. Compared with the patients in the low-risk group, those in the medium- and high-risk group had a significantly increased risk of recurrence with a hazard ratio (HR) of 1.75 (95% confidence interval [CI] 1.30-2.38) and 4.66 (95% CI 3.54-6.14), respectively. The results from the training set were validated in the testing set. Overall, our prognostic model incorporating readily available routine laboratory tests is powerful in identifying breast cancer patients who are at high risk of recurrence. Further study is warranted to validate its clinical application

Focal Spot, Summer/Fall 2007

https://digitalcommons.wustl.edu/focal_spot_archives/1106/thumbnail.jp

Focal Spot, Spring 2008

https://digitalcommons.wustl.edu/focal_spot_archives/1108/thumbnail.jp

Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice

Doxorubicin (DOX) is one of the most effective anti-cancer drugs in oncology, but may cause a cumulative dose-dependent cardiomyopathy in a number of cancer patients. The effect of DOX on the heart was studied in mice treated with i.v. injections of 2 mg/kg by measuring morphometric parameters, including nuclear index (number of non-myocytes/number of myocyte nuclei), reticulin index (reticulin area/number of myocyte transsections), nuclear transsectional area, myocyte transsectional area, capillary index (number of capillaries/number of myocyte transsections) and capillary transsectional area. The highest significant difference between control mice and DOX-treated mice was observed immediately after the 12th dose of DOX except for the two capillary parameters. The highest level of significance for these two parameters was obtained 12 weeks after the end of DOX treatment. In contrast to the observations in rats, mice did not develop a nephrotic syndrome during treatment with DOX. The morphometric analysis of myocardial changes in mice, as a quantitative and objective method, seems to be a good model for comparative studies on cardiomyopathy induced by anthracycline analogues

Initial Measurements with the PETsys TOFPET2 ASIC Evaluation Kit and a Characterization of the ASIC TDC

For a first characterization, we used the two KETEK-PM3325-WB SiPMs each equipped with a 3x3x5 mm${}^3$ LYSO scintillation crystal provided with the PETsys TOFPET2 ASIC Evaluation Kit. We changed the lower of two discriminator thresholds (D_T1) in the timing branch from vth_t1 = 5 - 30. The overvoltage was varied in a range of 1.25 V - 7.25 V. The ambient temperature was kept at 16{\deg}C. For all measurements, we performed an energy calibration including a correction for saturation. We evaluated the energy resolution, the coincidence resolving time (CRT) and the coincidence rate. At an overvoltage of 6 V, we obtained an energy resolution of about 10% FWHM, a CRT of approximately 210 ps FWHM and 400 ps FWTM, the coincidence rate showed only small variations of about 5%. To investigate the influence of the ambient temperature, it was varied between 12{\deg}C - 20{\deg}C. At 12{\deg}C and an overvoltage of 6.5 V, a CRT of approx. 195 ps FWHM and an energy resolution of about 9.5% FWHM could be measured. Observed satellite peaks in the time difference spectra were investigated in more detail. We could show that the location of the satellite peaks is correlated with a programmable delay element in the trigger circuit.Comment: This paper is under review with IEEE TRPMS. It has been presented in a talk at the PSMR 2018. This version of the manuscript was submitted as revision 2 to TRPMS after incrporating the comments of the reviewers. Only minor textchanges were made. Results, values and figures did not chang

Comparison of Path Tracking Flat Control and Working Point Linearization Based Set Point Control of Tumor Growth with Angiogenic Inhibition

Targeted molecular therapies (TMT) represent new perspectives in cancer treatment, fighting against the specific characteristic of the investigated tumor. Antiangiogenic therapy represents a specific TMT and its role is to stop the angiogenesis of the tumor, the process of forming new blood vessels; hence, to stop tumor growth. Proper control algorithms for tumor growth control with angiogenic inhibition are analyzed in the current article in order to find optimal therapeutic protocols. Two slightly different approaches are compared: nonlinear control by exact linearization with path tracking control, and linear control by working point linearization with set point control. The control strategies are compared in terms of the characteristics of the input signal (the inhibitor, drug intake) that is crucial if the therapy will be put into practice

Charge Transfer-oxy Radical Mechanism for Anti-cancer Agents

The proposal is advanced that anti-cancer drugs generally function by charge transfer resulting in formation of toxic oxy radicals which destroy the neoplasm. Electrochemical studies were performed with some of the main types of agents: iminium ions (adenine iminium from alkylating species, iminium metabolite of 6-mercaptopurine, nitidine, other polynuclear iminiums) and metal complexes (Pt(II)diaquodiammine-guanosine, copper salicylaldoximes). Reduction potentials ranged from -0.4 to -1.2 V. Literature data for quinones are presented and radiation is discussed. Based on the theoretical framework, a rationale is offered for the carcinogen-anti-cancer paradox and the role of antioxidants

KRAS early testing. Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting

KRAS testing is relevant for the choice of the most appropriate first-line therapy of metastatic colorectal cancer (CRC). Strategies for preventing unequal access to the test should be implemented, but their relevance in the practice is related to economic sustainability. The study adopted the Delphi technique to reach a consensus on several topics. Issues related to execution of KRAS testing were identified by an expert's board and proposed to 108 Italian oncologists and pathologists through two subsequent questionnaires. The emerging proposal was evaluated by decision analyses models employed by technology assessment agencies in order to assess cost-effectiveness. Alternative therapeutic strategies included most commonly used chemotherapy regimens alone or in combination with cetuximab or bevacizumab. The survey indicated that time interval for obtaining KRAS test should not exceed 15 days, 10 days being an optimal interval. To assure the access to proper treatment, a useful strategy should be to anticipate the test after radical resection in patients at high risk of relapse. Early KRAS testing in high risk CRC patients generates incremental cost-effectiveness ratios between 6,000 and 13,000 Euro per quality adjusted life year (QALY) gained. In extensive sensitivity analyses ICER's were always below 15,000 Euro per QALY gained, far within the threshold of 60,000 Euro/QALY gained accepted by regulatory institutions in Italy. In metastatic CRC a time interval higher than 15 days for result of KRAS testing limits access to therapeutic choices. Anticipating KRAS testing before the onset of metastatic disease in patients at high risk does not affect the sustainability and cost-effectiveness profile of cetuximab in first-line mCRC. Early KRAS testing may prevent this inequality in high-risk patients, whether they develop metastases, and is a cost-effective strategy. Based on these results, present joined recommendations of Italian societies of Oncology and Pathology should be updated including early KRAS testing